During the last three months, 17 analysts shared their evaluations of Blueprint Medicines (NASDAQ:BPMC), revealing diverse outlooks from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 8 | 5 | 3 | 0 | 1 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 1 | 0 | 0 | 0 |
| 2M Ago | 4 | 2 | 3 | 0 | 1 |
| 3M Ago | 3 | 2 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Blueprint Medicines, presenting an average target of $116.35, a high estimate of $168.00, and a low estimate of $75.00. Witnessing a positive shift, the current average has risen by 14.52% from the previous average price target of $101.60.
Investigating Analyst Ratings: An Elaborate Study
The standing of Blueprint Medicines among financial...
Login or create a forever free account to read this news
Sign up/Log in